A six-month, open-label, crossover study of the maintenance of serum testosterone and PSA [prostate-specific antigen] suppression after switching between Lupron [leuprorelin] 22.5 mg and Eligard [leuprorelin] 22.5 mg or Zoladex [goserelin] 10.8 mg and Eligard 22.5 mg in patients with advanced prostate cancer

Trial Profile

A six-month, open-label, crossover study of the maintenance of serum testosterone and PSA [prostate-specific antigen] suppression after switching between Lupron [leuprorelin] 22.5 mg and Eligard [leuprorelin] 22.5 mg or Zoladex [goserelin] 10.8 mg and Eligard 22.5 mg in patients with advanced prostate cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2006

At a glance

  • Drugs Goserelin (Primary) ; Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top